AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting

Elaine Maggi, Cristina Montagna

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The American Association for Cancer Research (AACR) Precision Medicine Series "Integrating Clinical Genomics and Cancer Therapy" took place June 13-16, 2015 in Salt Lake City, Utah. The conferencewas co-chaired by Charles L. Sawyers form Memorial Sloan Kettering Cancer Center in New York, ElaineR. Mardis form Washington University School of Medicine in St. Louis, and Arul M. Chinnaiyan fromUniversity of Michigan in Ann Arbor. About 500 clinicians, basic science investigators, bioinformaticians, and postdoctoral fellows joinedtogether to discuss the current state of Clinical Genomics and the advances and challenges of integratingNext Generation Sequencing (NGS) technologies into clinical practice. The plenary sessions and paneldiscussions covered current platforms and sequencing approaches adopted for NGS assays of cancergenome at several national and international institutions, different approaches used to map and classifytargetable sequence variants, and how information acquired with the sequencing of the cancer genome isused to guide treatment options. While challenges still exist from a technological perspective, it emergedthat there exists considerable need for the development of tools to aid the identification of the therapymost suitable based on the mutational profile of the somatic cancer genome. The process to match patientsto ongoing clinical trials is still complex. In addition, the need for centralized data repositories, preferablylinked to well annotated clinical records, that aid sharing of sequencing information is central to beginunderstanding the contribution of variants of unknown significance to tumor etiology and response totherapy. Here we summarize the highlights of this stimulating four-day conference with a major emphasison the open problems that the clinical genomics community is currently facing and the tools most neededfor advancing this field.

Original languageEnglish (US)
Pages (from-to)44-51
Number of pages8
JournalMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Volume782
DOIs
StatePublished - Dec 1 2015

Fingerprint

Precision Medicine
Genomics
Research
Neoplasms
Genome
L Forms
Therapeutics
Information Dissemination
Research Personnel
Medicine
Clinical Trials
Technology

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Health, Toxicology and Mutagenesis

Cite this

@article{2b3994d853f548e791d4cf8888f255a3,
title = "AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting",
abstract = "The American Association for Cancer Research (AACR) Precision Medicine Series {"}Integrating Clinical Genomics and Cancer Therapy{"} took place June 13-16, 2015 in Salt Lake City, Utah. The conferencewas co-chaired by Charles L. Sawyers form Memorial Sloan Kettering Cancer Center in New York, ElaineR. Mardis form Washington University School of Medicine in St. Louis, and Arul M. Chinnaiyan fromUniversity of Michigan in Ann Arbor. About 500 clinicians, basic science investigators, bioinformaticians, and postdoctoral fellows joinedtogether to discuss the current state of Clinical Genomics and the advances and challenges of integratingNext Generation Sequencing (NGS) technologies into clinical practice. The plenary sessions and paneldiscussions covered current platforms and sequencing approaches adopted for NGS assays of cancergenome at several national and international institutions, different approaches used to map and classifytargetable sequence variants, and how information acquired with the sequencing of the cancer genome isused to guide treatment options. While challenges still exist from a technological perspective, it emergedthat there exists considerable need for the development of tools to aid the identification of the therapymost suitable based on the mutational profile of the somatic cancer genome. The process to match patientsto ongoing clinical trials is still complex. In addition, the need for centralized data repositories, preferablylinked to well annotated clinical records, that aid sharing of sequencing information is central to beginunderstanding the contribution of variants of unknown significance to tumor etiology and response totherapy. Here we summarize the highlights of this stimulating four-day conference with a major emphasison the open problems that the clinical genomics community is currently facing and the tools most neededfor advancing this field.",
author = "Elaine Maggi and Cristina Montagna",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.mrfmmm.2015.10.005",
language = "English (US)",
volume = "782",
pages = "44--51",
journal = "Mutation Research",
issn = "0027-5107",
publisher = "Elsevier",

}

TY - JOUR

T1 - AACR precision medicine series

T2 - Highlights of the integrating clinical genomics and cancer therapy meeting

AU - Maggi, Elaine

AU - Montagna, Cristina

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The American Association for Cancer Research (AACR) Precision Medicine Series "Integrating Clinical Genomics and Cancer Therapy" took place June 13-16, 2015 in Salt Lake City, Utah. The conferencewas co-chaired by Charles L. Sawyers form Memorial Sloan Kettering Cancer Center in New York, ElaineR. Mardis form Washington University School of Medicine in St. Louis, and Arul M. Chinnaiyan fromUniversity of Michigan in Ann Arbor. About 500 clinicians, basic science investigators, bioinformaticians, and postdoctoral fellows joinedtogether to discuss the current state of Clinical Genomics and the advances and challenges of integratingNext Generation Sequencing (NGS) technologies into clinical practice. The plenary sessions and paneldiscussions covered current platforms and sequencing approaches adopted for NGS assays of cancergenome at several national and international institutions, different approaches used to map and classifytargetable sequence variants, and how information acquired with the sequencing of the cancer genome isused to guide treatment options. While challenges still exist from a technological perspective, it emergedthat there exists considerable need for the development of tools to aid the identification of the therapymost suitable based on the mutational profile of the somatic cancer genome. The process to match patientsto ongoing clinical trials is still complex. In addition, the need for centralized data repositories, preferablylinked to well annotated clinical records, that aid sharing of sequencing information is central to beginunderstanding the contribution of variants of unknown significance to tumor etiology and response totherapy. Here we summarize the highlights of this stimulating four-day conference with a major emphasison the open problems that the clinical genomics community is currently facing and the tools most neededfor advancing this field.

AB - The American Association for Cancer Research (AACR) Precision Medicine Series "Integrating Clinical Genomics and Cancer Therapy" took place June 13-16, 2015 in Salt Lake City, Utah. The conferencewas co-chaired by Charles L. Sawyers form Memorial Sloan Kettering Cancer Center in New York, ElaineR. Mardis form Washington University School of Medicine in St. Louis, and Arul M. Chinnaiyan fromUniversity of Michigan in Ann Arbor. About 500 clinicians, basic science investigators, bioinformaticians, and postdoctoral fellows joinedtogether to discuss the current state of Clinical Genomics and the advances and challenges of integratingNext Generation Sequencing (NGS) technologies into clinical practice. The plenary sessions and paneldiscussions covered current platforms and sequencing approaches adopted for NGS assays of cancergenome at several national and international institutions, different approaches used to map and classifytargetable sequence variants, and how information acquired with the sequencing of the cancer genome isused to guide treatment options. While challenges still exist from a technological perspective, it emergedthat there exists considerable need for the development of tools to aid the identification of the therapymost suitable based on the mutational profile of the somatic cancer genome. The process to match patientsto ongoing clinical trials is still complex. In addition, the need for centralized data repositories, preferablylinked to well annotated clinical records, that aid sharing of sequencing information is central to beginunderstanding the contribution of variants of unknown significance to tumor etiology and response totherapy. Here we summarize the highlights of this stimulating four-day conference with a major emphasison the open problems that the clinical genomics community is currently facing and the tools most neededfor advancing this field.

UR - http://www.scopus.com/inward/record.url?scp=84946558581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946558581&partnerID=8YFLogxK

U2 - 10.1016/j.mrfmmm.2015.10.005

DO - 10.1016/j.mrfmmm.2015.10.005

M3 - Article

C2 - 26554403

AN - SCOPUS:84946558581

VL - 782

SP - 44

EP - 51

JO - Mutation Research

JF - Mutation Research

SN - 0027-5107

ER -